Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

20.08 -0.46 (-2.24%)
Streaming Delayed Price Updated: 12:30 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
1 Stock Up by 63% This Year That Could Double, According to Wall Street
Some math suggests that even Wall Street is lowballing the stock's potential. 
Via The Motley Fool
What Analysts Are Saying About Intellia Therapeutics Stock
 
Via Benzinga
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
The growth investor kicked off this week buying up some high-flying stocks. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Topics Artificial Intelligence
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary... 
Via Benzinga
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Tesla To Rally More Than 31%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Expert Outlook: Intellia Therapeutics Through The Eyes Of 5 Analysts
 
Via Benzinga
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff. 
Via Benzinga
Topics ETFs Economy
Intellia Therapeutics Shares Are Ripping Higher: Here's Why
Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones. 
Via Benzinga
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews
 
Via Benzinga
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Intellia (NTLA) Q2 Revenue Jumps 106%
Via The Motley Fool
Intellia Therapeutics Inc (NASDAQ:NTLA) Q2 2025 Earnings: Revenue Surpasses Estimates, Losses Narrower Than Expected
Intellia Therapeutics (NTLA) reported Q2 2025 revenue of $14.25M, beating estimates, with a narrower loss of $0.99 per share. Stock rose 2% pre-market amid strong clinical progress in CRISPR... 
Via Chartmill
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
Via MarketBeat
Topics Economy Stocks
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US. 
Via Benzinga
FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering
FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research 
Via Benzinga
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate. 
Via Benzinga
Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.